Clinical Trial

Clinical Research of Tapering UDCA in PBC Patients With a Complete Response

Study acronym: UDCA PBC
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 1, 2025 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
This study explores the feasibility of the reducing medication regimen for Ursodeoxycholic Acid(UDCA) in the treatment of primary biliary cholangitis. The participants will be distributed randomly into two experimental groups and one control group. The two experimental groups will receive reduced dosage of UDCA at different level, while the control group will receive standard dosage of UDCA. The effect of therapy will be evaluated every three months.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-11-30; most recent amendment 2025-03-26.
Trial Details
NCT Number NCT04650243
Lead Sponsor Peking Union Medical College Hospital
Conditions Primary Biliary Cholangitis
Enrollment 90 participants
Start Date 2020-01-21
Primary Completion 2025-05 (estimated)
Study Completion 2025-05 (estimated)
Updated on ClinicalTrials.gov 2025-04-01